Metropolitan Life Insurance Company (MetLife)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,766	Closed	-$46.2K	–	2841
2021 Q3	$46.2K	Sell	5,766 -5,494	-49%	-$54.2K	﹤0.01%	2769
2021 Q2	$128K	Buy	+11,260	New	+$113K	﹤0.01%	2462
2014 Q4	–	Sell	-191	Closed	-$286K	–	2676
2014 Q3	$286K	Buy	191 +4	+2%	+$5.79K	﹤0.01%	2114
2014 Q2	$256K	Buy	187 +50	+36%	+$58K	﹤0.01%	2330
2014 Q1	$190K	Buy	+137	New	+$159K	﹤0.01%	2496
2013 Q3	–	Sell	-134	Closed	-$147K	–	2773
2013 Q2	$147K	Buy	+134	New	+$149K	﹤0.01%	2561

Other funds holding VIRX

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VIRX Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 5,766 shares — an estimated $46.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VIRX in Q2 2013 and held it in 6 quarters. The position peaked at $286K in Q3 2014. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 5,766 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $46.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
Metropolitan Life Insurance Company (MetLife)'s Viracta Therapeutics, Inc. Common Stock position peaked at $286K in Q3 2014.
69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.